blood samples + nasal swabs
Pre-clinicalCompleted 0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Staphylococcus Aureus
Conditions
Staphylococcus Aureus
Trial Timeline
Dec 14, 2017 → Dec 7, 2020
NCT ID
NCT03643328About blood samples + nasal swabs
blood samples + nasal swabs is a pre-clinical stage product being developed by Sanofi for Staphylococcus Aureus. The current trial status is completed. This product is registered under clinical trial identifier NCT03643328. Target conditions include Staphylococcus Aureus.
What happened to similar drugs?
2 of 4 similar drugs in Staphylococcus Aureus were approved
Approved (2) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
3
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03643328 | Pre-clinical | Completed |
Competing Products
12 competing products in Staphylococcus Aureus
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Dalbavancin + Vancomycin + Oxacillin + Flucloxacillin + Cefadroxil + Clindamycin | AbbVie | Phase 3 | 40 |
| AZD7760 | AstraZeneca | Phase 1/2 | 39 |
| V710 + Placebo | Merck | Phase 2/3 | 30 |
| Daptomycin | Merck | Phase 2 | 35 |
| Comparator: Placebo (PBO) + V710 Comparator: Placebo (PBO) + V710 Comparator: Placebo (PBO) + V710 Comparator: Placebo (PBO) + V710 Comparator: Placebo (PBO) + V710 Comparator: Placebo (PBO) | Merck | Phase 2 | 35 |
| Imipenem/cilastatin | Pfizer | Approved | 39 |
| linezolid (Zyvox) + vancomycin | Pfizer | Approved | 43 |
| Linezolid + Vancomycin | Pfizer | Pre-clinical | 26 |
| Aurexis® | Bristol Myers Squibb | Phase 2 | 35 |
| Aurexis® (tefibazumab) | Bristol Myers Squibb | Phase 2 | 35 |
| Ceftobiprole medocaril + Daptomycin | Basilea Pharmaceutica | Phase 3 | 34 |
| 514G3 (2 mg/kg) plus standard IV antibiotic treatment + 514G3 (10 mg/kg) plus standard IV antibiotic treatment + 514G3 (40 mg/kg) plus standard IV antibiotic treatment + 514G3 (40 mg/kg) plus standard IV antibiotic treatment: Phase II | XBiotech | Phase 1/2 | 22 |